DEA Orders Action Against Physician Hil Rizvi's Practice
Published Date: 10/21/2025
Notice
Summary
Dr. Hil Rizvi from Utah tried to get a DEA registration but got denied because he lied on his application. The DEA found he didn’t tell the truth about important questions, which risks public safety. This decision means Dr. Rizvi won’t get his registration, and the denial is final as of early 2025.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA registration denied for Dr. Hil Rizvi
You (Hil Rizvi, M.D.) had your pending DEA application (Control No. W24074770C) denied. The Order denies that application and any other pending application of yours in Utah, effective November 20, 2025.
Denial based on material falsification of application
DEA found your June 11, 2024 application omitted required details about adverse state licensure actions and concluded those omissions were material under 21 U.S.C. 824(a)(1). The decision identifies omitted actions including West Virginia revocation (Aug 17, 1999), Vermont suspension (Sept 2, 1999), New Hampshire revocation (Jan 13, 2021), Oklahoma denial (Sept 14, 2023), and New Mexico denial (May 10, 2023), and relies on those omissions to deny the application.
Applicant found in default; hearing rights waived
The DEA found you in default for failing to timely request or properly file a hearing under 21 CFR 1301.43 after the Order to Show Cause, and you waived your right to a hearing. Because of that default, the factual allegations in the OSC were deemed admitted and formed the basis for the final denial.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19611, Enyibuaku Uzoaga, M.D.; Decision and Order
Dr. Enyibuaku Uzoaga from Houston wanted a DEA registration to prescribe controlled substances, but the DEA denied her because she’s been kicked out of Medicare, Medicaid, and other federal health programs due to health care fraud. After a hearing and review, the DEA confirmed the denial, meaning she can’t legally get this registration anytime soon. This decision affects Dr. Uzoaga’s ability to work with controlled drugs and impacts her medical practice and income.
Next: 2025-19613, MCRGC, LLC; Decision and Order
MCRGC, LLC wanted to grow marijuana but didn’t have the right licenses, a real location, or proper agreements, so the DEA said no to their application. Since MCRGC didn’t ask for a hearing or fix these issues, their request got denied for good. This means MCRGC can’t legally grow marijuana, and anyone applying must have all paperwork and approvals in place to avoid the same fate.